TY - JOUR
T1 - Efficacy of a sleep health intervention to optimize standard smoking cessation treatment response
T2 - Results from a pilot randomized controlled trial
AU - Patterson, Freda
AU - Grandner, Michael A.
AU - Malone, Susan K.
AU - Pohlig, Ryan T.
AU - Ashare, Rebecca L.
AU - Edwards, David G.
N1 - Publisher Copyright: © The Author(s), 2020. Published by Cambridge University Press.
PY - 2020
Y1 - 2020
N2 - BackgroundWe tested if an adjunctive sleep health (SH) intervention improved smoking cessation treatment response by increasing quit rates. We also examined if baseline sleep, and improvements in sleep in the first weeks of quitting, were associated with quitting at the end of treatment.MethodsTreatment-seeking smokers (N = 29) aged 21-65 years were randomized to a SH intervention (n = 16), or general health (GH) control (n = 13) condition. Participants received six counseling sessions across 15-weeks: SH received smoking cessation + SH counseling; GH received smoking cessation + GH counseling. Counseling began 4-weeks before the target quit date (TQD), and varenicline treatment began 1-week prior to TQD. Smoking status and SH were assessed at baseline (week 1), TQD (week 4), 3 weeks after cessation (week 7), week 12, and at the end of treatment (EOT; week 15).ResultsSH versus GH participants had higher Carbon Monoxide (CO) -verified, 7-day point prevalence abstinence at EOT (69% vs. 54%, respectively; adjusted odds ratio (aOR) = 2.10, 95% confidence interval (CI) = 0.40-10.69, P = 0.77). Higher baseline sleep efficiency (aOR = 1.42, 95% CI = 1.03-1.96, P = 0.03), predicted higher EOT cessation. Models were adjusted for age, sex, education, and baseline nicotine dependence.ConclusionsImproving SH in treatment-seeking smokers prior to cessation warrants further examination as a viable strategy to promote cessation.
AB - BackgroundWe tested if an adjunctive sleep health (SH) intervention improved smoking cessation treatment response by increasing quit rates. We also examined if baseline sleep, and improvements in sleep in the first weeks of quitting, were associated with quitting at the end of treatment.MethodsTreatment-seeking smokers (N = 29) aged 21-65 years were randomized to a SH intervention (n = 16), or general health (GH) control (n = 13) condition. Participants received six counseling sessions across 15-weeks: SH received smoking cessation + SH counseling; GH received smoking cessation + GH counseling. Counseling began 4-weeks before the target quit date (TQD), and varenicline treatment began 1-week prior to TQD. Smoking status and SH were assessed at baseline (week 1), TQD (week 4), 3 weeks after cessation (week 7), week 12, and at the end of treatment (EOT; week 15).ResultsSH versus GH participants had higher Carbon Monoxide (CO) -verified, 7-day point prevalence abstinence at EOT (69% vs. 54%, respectively; adjusted odds ratio (aOR) = 2.10, 95% confidence interval (CI) = 0.40-10.69, P = 0.77). Higher baseline sleep efficiency (aOR = 1.42, 95% CI = 1.03-1.96, P = 0.03), predicted higher EOT cessation. Models were adjusted for age, sex, education, and baseline nicotine dependence.ConclusionsImproving SH in treatment-seeking smokers prior to cessation warrants further examination as a viable strategy to promote cessation.
KW - Sleep health
KW - smoking cessation
KW - varenicline
UR - http://www.scopus.com/inward/record.url?scp=85081641571&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081641571&partnerID=8YFLogxK
U2 - 10.1017/jsc.2020.8
DO - 10.1017/jsc.2020.8
M3 - Article
SN - 1834-2612
JO - Journal of Smoking Cessation
JF - Journal of Smoking Cessation
ER -